Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18324802 | 0.91 | MAPT (0.52) | MAPTLMNA | |
| SCHEMBL16801687 | 0.85 | SLC6A4 (0.69) | SLC6A4 | |
| SCHEMBL16801553 | 0.85 | SLC6A4 (0.67) | MAPTSLC6A4LMNA | |
| SCHEMBL16801734 | 0.83 | SLC6A4 (0.69) | MAPTSLC6A4LMNA | |
| SCHEMBL4672856 | 0.83 | SLC6A4 (0.72) | SLC6A4LMNA | |
| SCHEMBL16801779 | 0.81 | SLC6A4 (0.70) | MAPTSLC6A4 | |
| SCHEMBL18324766 | 0.81 | SLC6A4 (0.49) | MAPTSLC6A4LMNA | |
| SCHEMBL18324812 | 0.80 | TDO2 (0.67) | SLC6A4 | |
| SCHEMBL16801569 | 0.80 | SLC6A4 (0.71) | SLC6A4 | |
| SCHEMBL11864713 | 0.80 | LMNA (0.66) | MAPTSLC6A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082802-B1 | TRYPTOPHAN-2,3-DIOXYGENASE (TDO) AND/OR INDOLAMINE-2,3-DIOXYGENASE (IDO) INHIBITORS AND THEIR USE | IOMET PHARMA LTD (GB) | 2020-02-26 | — | — | EP | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367564-A1 | Pharmaceutical Compound | TDO2, IDO1, IDO2 | MAPT 2964/4885SLC6A4 73/4885LMNA 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.